Reviewing 111 (NASDAQ:YI) and Cigna Group (NYSE:CI)

Cigna Group (NYSE:CI) and 111 (NASDAQ:YI) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations for Cigna Group and 111, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cigna Group	0	8	15	0	2.65
111	1	0	0	0	1.00

Cigna Group presently has a consensus price target of $338.24, indicating a potential upside of 19.84%. Given Cigna Group’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Cigna Group is more favorable than 111.

Volatility and Risk

Cigna Group has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, 111 has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Institutional & Insider Ownership

87.0% of Cigna Group shares are owned by institutional investors. Comparatively, 21.3% of 111 shares are owned by institutional investors. 0.6% of Cigna Group shares are owned by company insiders. Comparatively, 43.9% of 111 shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Cigna Group and 111’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cigna Group	2.27%	19.75%	5.34%
111	-1.01%	N/A	-4.86%

Valuation and Earnings

This table compares Cigna Group and 111″s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cigna Group	$274.90 billion	0.27	$5.96 billion	$24.17	11.68
111	$1.80 billion	0.02	-$9.65 million	($1.60)	-1.97

Cigna Group has higher revenue and earnings than 111. 111 is trading at a lower price-to-earnings ratio than Cigna Group, indicating that it is currently the more affordable of the two stocks.

Summary

Cigna Group beats 111 on 12 of the 14 factors compared between the two stocks.

About Cigna Group

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.

About 111

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.